BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24654220)

  • 1. Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer: the European Pharmacogenetic Opioid Study (EPOS).
    Fladvad T; Fayers P; Skorpen F; Kaasa S; Klepstad P
    BMJ Support Palliat Care; 2012 Dec; 2(4):351-5. PubMed ID: 24654220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients.
    Klepstad P; Fladvad T; Skorpen F; Bjordal K; Caraceni A; Dale O; Davies A; Kloke M; Lundström S; Maltoni M; Radbruch L; Sabatowski R; Sigurdardottir V; Strasser F; Fayers PM; Kaasa S;
    Pain; 2011 May; 152(5):1139-1145. PubMed ID: 21398039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Loci modulate opioid therapy response for cancer pain.
    Galvan A; Skorpen F; Klepstad P; Knudsen AK; Fladvad T; Falvella FS; Pigni A; Brunelli C; Caraceni A; Kaasa S; Dragani TA
    Clin Cancer Res; 2011 Jul; 17(13):4581-7. PubMed ID: 21622719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients.
    Weschules DJ; Bain KT; Reifsnyder J; McMath JA; Kupperman DE; Gallagher RM; Hauck WW; Knowlton CH
    Pain Med; 2006; 7(4):320-9. PubMed ID: 16898943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic influences on oxycodone response characteristics in human experimental pain.
    Olesen AE; Sato H; Nielsen LM; Staahl C; Droney J; Gretton S; Branford R; Drewes AM; Arendt-Nielsen L; Riley J; Ross J
    Fundam Clin Pharmacol; 2015 Aug; 29(4):417-25. PubMed ID: 26042474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
    J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
    Barratt DT; Bandak B; Klepstad P; Dale O; Kaasa S; Christrup LL; Tuke J; Somogyi AA
    Pharmacogenet Genomics; 2014 Apr; 24(4):185-94. PubMed ID: 24469018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients.
    Riley J; Ross JR; Rutter D; Wells AU; Goller K; du Bois R; Welsh K
    Support Care Cancer; 2006 Jan; 14(1):56-64. PubMed ID: 15952009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial.
    Sima L; Fang WX; Wu XM; Li F
    J Clin Pharm Ther; 2012 Feb; 37(1):27-31. PubMed ID: 21208247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose.
    Hall S; Gallagher RM; Gracely E; Knowlton C; Wescules D
    Pain Med; 2003 Jun; 4(2):125-34. PubMed ID: 12873262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
    Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of oxycodone in cancer-related pain: a literature review.
    Cairns R
    Int J Palliat Nurs; 2001 Nov; 7(11):522-7. PubMed ID: 11775926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy switching in patients receiving long-acting opioids.
    Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
    Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
    Slatkin NE; Xie F; Messina J; Segal TJ
    J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.
    Fladvad T; Klepstad P; Langaas M; Dale O; Kaasa S; Caraceni A; Skorpen F
    Pharmacogenet Genomics; 2013 Mar; 23(3):117-26. PubMed ID: 23277092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.